Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, Cornell University, New York, NY 10065, USA.
Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, Cornell University, New York, NY 10065, USA.
Immunity. 2016 May 17;44(5):1069-78. doi: 10.1016/j.immuni.2016.04.023.
Checkpoint-blocking antibodies can generate potent anti-tumor responses by encouraging the immune system to seek and destroy cancer cells. At this time, the United States Food and Drug Administration has approved three checkpoint-blocking antibodies in three disease indications, and additional approvals are expected to broaden the clinical scope of immunotherapy. Herein, we review the clinical development of CTLA-4-, PD-1-, and PD-L1-blocking antibodies across tumor types and briefly discuss areas of active investigation of potential biomarkers.
检查点阻断抗体可以通过鼓励免疫系统寻找和摧毁癌细胞来产生强大的抗肿瘤反应。目前，美国食品和药物管理局已在三种疾病适应证中批准了三种检查点阻断抗体，预计更多的批准将扩大免疫疗法的临床范围。在此，我们综述了 CTLA-4、PD-1 和 PD-L1 阻断抗体在各种肿瘤类型中的临床开发情况，并简要讨论了潜在生物标志物的活跃研究领域。
